Mirae Asset Global Investments Co. Ltd. raised its stake in Shire PLC (NASDAQ:SHPG) by 341.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,832 shares of the biopharmaceutical company’s stock after purchasing an additional 18,430 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Shire were worth $4,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Cornerstone Wealth Management LLC acquired a new stake in shares of Shire in the second quarter valued at approximately $145,000. CIBC Private Wealth Group LLC increased its holdings in shares of Shire by 22.6% in the second quarter. CIBC Private Wealth Group LLC now owns 43,358 shares of the biopharmaceutical company’s stock valued at $7,319,000 after purchasing an additional 8,005 shares in the last quarter. Linscomb & Williams Inc. acquired a new stake in shares of Shire in the second quarter valued at approximately $210,000. Greenleaf Trust increased its holdings in shares of Shire by 32.0% in the second quarter. Greenleaf Trust now owns 3,194 shares of the biopharmaceutical company’s stock valued at $539,000 after purchasing an additional 774 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Shire by 1,634.4% in the second quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock valued at $32,671,000 after purchasing an additional 182,388 shares in the last quarter. Institutional investors own 20.49% of the company’s stock.
SHPG opened at $172.75 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.92 and a quick ratio of 0.51. Shire PLC has a 52 week low of $123.73 and a 52 week high of $182.47. The firm has a market cap of $54.14 billion, a price-to-earnings ratio of 11.60, a price-to-earnings-growth ratio of 1.60 and a beta of 1.01.
Shire (NASDAQ:SHPG) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing analysts’ consensus estimates of $3.65 by ($0.01). Shire had a return on equity of 12.70% and a net margin of 30.63%. The business had revenue of $3.87 billion for the quarter. During the same period in the previous year, the company earned $3.81 earnings per share. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Equities analysts expect that Shire PLC will post 15.09 EPS for the current year.
SHPG has been the subject of a number of research reports. Sanford C. Bernstein lowered shares of Shire from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 4th. Royal Bank of Canada set a $195.00 price target on shares of Shire and gave the company a “buy” rating in a report on Tuesday, October 23rd. Evercore ISI lowered shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price target for the company. in a report on Tuesday, September 4th. ValuEngine raised shares of Shire from a “sell” rating to a “hold” rating in a report on Friday, September 21st. Finally, BidaskClub raised shares of Shire from a “sell” rating to a “hold” rating in a report on Thursday, September 13th. Nine analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $201.11.
TRADEMARK VIOLATION WARNING: This piece was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2018/12/08/mirae-asset-global-investments-co-ltd-has-4-32-million-holdings-in-shire-plc-shpg.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
See Also: What is the NASDAQ?
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.